Evidence map›Paper›PMID 29143281›Full record

ArticleInternational journal of hematology2018

Long-term outcome in patients treated at home during the pancytopenic phase after allogeneic haematopoietic stem cell transplantation.

Olle Ringdén, Behnam Sadeghi, Gianluca Moretti, Sigrun Finnbogadottir, Brita Eriksson, Jonas Mattsson, Britt-Marie Svahn, Mats Remberger

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. [Protective environment strategies for hematopoietic stem cell transplantation: progress and prospects].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2024
    Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Olle RingdénDepartment of LABMED, Translational Cell Therapy Research Group (TCR), Karolinska Institutet, Kliniskt Forskningscentrum (KFC), NOVUM Plan 6, Hälsovägen 7-9, 141 57, Huddinge, Sweden. olle.ringden@ki.se.ORCID http://orcid.org/0000-0002-6092-1536
Behnam SadeghiDepartment of LABMED, Translational Cell Therapy Research Group (TCR), Karolinska Institutet, Kliniskt Forskningscentrum (KFC), NOVUM Plan 6, Hälsovägen 7-9, 141 57, Huddinge, Sweden.
Gianluca MorettiDepartment of LABMED, Translational Cell Therapy Research Group (TCR), Karolinska Institutet, Kliniskt Forskningscentrum (KFC), NOVUM Plan 6, Hälsovägen 7-9, 141 57, Huddinge, Sweden.
Sigrun FinnbogadottirDepartment of LABMED, Translational Cell Therapy Research Group (TCR), Karolinska Institutet, Kliniskt Forskningscentrum (KFC), NOVUM Plan 6, Hälsovägen 7-9, 141 57, Huddinge, Sweden.
Brita ErikssonDepartment of LABMED, Translational Cell Therapy Research Group (TCR), Karolinska Institutet, Kliniskt Forskningscentrum (KFC), NOVUM Plan 6, Hälsovägen 7-9, 141 57, Huddinge, Sweden.
Jonas MattssonDepartment of LABMED, Translational Cell Therapy Research Group (TCR), Karolinska Institutet, Kliniskt Forskningscentrum (KFC), NOVUM Plan 6, Hälsovägen 7-9, 141 57, Huddinge, Sweden.
Britt-Marie SvahnDepartment of LABMED, Translational Cell Therapy Research Group (TCR), Karolinska Institutet, Kliniskt Forskningscentrum (KFC), NOVUM Plan 6, Hälsovägen 7-9, 141 57, Huddinge, Sweden.
Mats RembergerDepartment of LABMED, Translational Cell Therapy Research Group (TCR), Karolinska Institutet, Kliniskt Forskningscentrum (KFC), NOVUM Plan 6, Hälsovägen 7-9, 141 57, Huddinge, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients undergoing allogeneic haematopoietic stem cell transplantation (HSCT) were given the option to be treated at home during the pancytopenic phase. Daily visits by a nurse and phone calls from a physician from the unit were part of the protocol. During almost two decades, 252 patients with haematological malignancies and non-malignant disorders were included. Median age was 47 (range 0-72) years. Myeloablative conditioning was given to 102 patients and reduced intensity to 150. Donors were matched unrelated (n = 160), HLA-identical siblings (n = 71), or HLA-mismatched (n = 21). Cumulative incidence of acute graft-versus-host disease (GVHD) was 35% and that of chronic GVHD was 46%. Non-relapse mortality was 14% 10 years after HSCT. In patients with haematological malignancies (n = 229), the 10-year probability of relapse was 34%. No patients died at home. Overall survival was 59% and relapse-free survival was 50% after 10 years. We conclude that patients treated at home after HSCT have an encouraging long-term outcome.

Indexed as

Hematopoietic Stem Cell TransplantationHome Care ServicesPancytopeniaPostoperative ComplicationsAcute DiseaseAdolescentAdultAgedAllograftsChildChild, PreschoolChronic DiseaseDisease-Free SurvivalFemaleGraft vs Host DiseaseHematologic NeoplasmsHLA AntigensAllogeneic hematopoietic stem cell transplantationGraft-versus-host diseaseHome careNeutropenia

Identifiers

PMID29143281

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.